Valeant Pharmaceuticals Intl Inc. Crushed by Citron Research: Find Out Who’s Next

Andrew Left of Citron Research has another top pick for short-sellers looking for another opportunity to capitalize on accounting manipulations and scandals to reap a massive pay day, as with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

For short-sellers looking for another opportunity to capitalize on accounting manipulations and scandals to reap a massive pay day, as with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), Andrew Left from Citron Research has another top pick for you.

Mr. Left has asserted that now may be the time to short TransDigm Group Incorporated (NYSE:TDG) according to a report his firm released January 20.

The report outlined a number of reasons why TransDigm is headed in a similar direction as Valeant and why right now may be the right time to initiate a short position in this company.

Who is TransDigm Group Incorporated?

The TransDigm CEO has stated that he believes TransDigm is one of the biggest unknown companies out there — operating largely under the radar. For a company with a market capitalization of over $12 billion, Citron Research appears to have created massive value for internal shareholders and the company’s CEO, who is now pulling in more than double the vast majority of his peers.

Over the past five years, Bloomberg has reported that TransDigm’s CEO has raked in $278 million with the closest two CEOs in a group of companies representing TransDigm’s competitors pulling in $150 million and the remainder making far less.

This newfound scrutiny is largely viewed by analysts as a negative for TransDigm, as the company has not had to deal with the proverbial “microscope” and the pitfalls such related short-side pressure may provide.

Unlike Valeant, which operates in the pharmaceutical industry, TransDigm is an aerospace parts supplier for the U.S. government and large aerospace manufacturers such as Boeing Co. and Lockheed Martin Corporation.

Like Valeant, TransDigm’s playbook involves acquisitions and price hikes to boost margins in an industry where margins and profitability are king. Acquisitions, such as the 2013 purchase of vibration panels maker Aerosonic for $39 million dollars, show how TransDigm chooses its targets: it picks companies with unique replacement parts that are rarely produced and it hikes prices post-acquisition.

The problem with this corporate strategy

As investors discovered with Valeant, the major problem with implementing a corporate strategy of “acquire first, hike prices shortly thereafter” is that eventually, the resulting debt load gets to the point where raising money for acquisitions becomes very expensive, and the number of companies to acquire will thin out, presenting fewer “low-hanging fruit” opportunities for bolt-on acquisitions.

TransDigm’s bond rating appears to be stable for now; Moody’s Corporation assigned a Ba2 rating to the company’s most recent bond issue for $1.2 billion.

That said, the company’s largest outstanding bond for $1.6 billion is coming due at the end of 2018, meaning management will need to decide at that time whether raising more debt to make the bond repayment makes the most sense or if it has to use its earnings to pay out a portion of the bond due.

In 2016, the company earned $586 million on $3.17 billion in sales, meaning additional debt raises are likely to come in the next few years.

Right now, it makes sense to just wait and see how accurate Mr. Left’s prediction will be over the next few quarters.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Moody's, TransDigm Group, and Valeant Pharmaceuticals.

More on Investing

potted green plant grows up in arrow shape
Stocks for Beginners

1 Canadian Growth Stock That Could Double Your Money in an Economic Recovery

The market downturn is an opportunity to lock growth during the economic recovery. This stock is a blend of value,…

Read more »

Bank sign on traditional europe building facade
Investing

RRSP Investors: Here’s the Best Canadian Bank Stock for Your Buck

Bank of Montreal (TSX:BMO)(NYSE:BMO) stock is getting far too cheap to ignore after the latest spill in the big Canadian…

Read more »

analyze data
Dividend Stocks

2 Safe Dividend Stocks That Could Help You Fight Inflation

A dependable stream of passive income is one way to help offset rising inflation rates. Here are two top dividend…

Read more »

edit Person using calculator next to charts and graphs
Dividend Stocks

Stay Invested in a Recession: Increase Positions in 2 Value Stocks

The suggestion of market analysts is to increase positions in two value stocks if you want to stay invested amid…

Read more »

Diagonal chain made of zeros and ones. Cryptocurrency and mining.
Cryptocurrency

Is This the End for Crypto?

Bitcoin (CRYPTO:ETH) is in the midst of its worst crash in years. Is this the end?

Read more »

Business success with growing, rising charts and businessman in background
Investing

4 Growth Stocks That Could Make You RICH by 2030

Canadians should take advantage of discounted growth stocks like goeasy Ltd. (TSX:GSY) and others in this summer bear market.

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Dividend Stocks

3 Dividend Stocks to Buy as Inflation Surges in Canada

If you're worried about how surging inflation may impact your portfolio, here are three of the best dividend stocks to…

Read more »

You Should Know This
Dividend Stocks

High Inflation: The Good and the Bad for Canadians

Consider tucking away some of your long-term savings in quality dividend stocks like Brookfield Infrastructure in this correction.

Read more »